1. Home
  2. SVRN vs HBIO Comparison

SVRN vs HBIO Comparison

Compare SVRN & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OceanPal Inc.

SVRN

OceanPal Inc.

HOLD

Current Price

$11.13

Market Cap

28.8M

ML Signal

HOLD

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

SELL

Current Price

$8.70

Market Cap

26.5M

Sector

Industrials

ML Signal

SELL

Company Overview

Basic Information
Metric
SVRN
HBIO
Founded
2021
1901
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Laboratory Analytical Instruments
Sector
Consumer Discretionary
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
28.8M
26.5M
IPO Year
2021
2000

Fundamental Metrics

Financial Performance
Metric
SVRN
HBIO
Price
$11.13
$8.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 52.3K
28.4K
Earning Date
12-01-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $116,176,000.00
Revenue This Year
N/A
$4.09
Revenue Next Year
N/A
$5.22
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.16
$0.40
52 Week High
$74.74
$10.20

Technical Indicators

Market Signals
Indicator
SVRN
HBIO
Relative Strength Index (RSI) 33.79 49.49
Support Level $6.67 $8.01
Resistance Level $13.51 $10.20
Average True Range (ATR) 2.57 0.58
MACD -0.28 -0.05
Stochastic Oscillator 2.16 29.04

Price Performance

Historical Comparison
SVRN
HBIO

About SVRN OceanPal Inc.

SVRN Inc is focused on digital asset management and the development and adoption of blockchain-based technologies, with activities centered on NEAR Protocol. Its activities include managing a digital asset treasury with NEAR as a principal asset, supporting the commercial adoption of NEAR-related products, and investing in, developing, and acquiring ventures related to blockchain and digital assets.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: